← Back to patent-cliff list
Prexigebersen
Tier C — Watch / tradePrexigebersen
Bio-Path Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：GRB2
Indications (approved)：Acute myeloid leukaemia, Peritoneal cancer, Epithelial ovarian cancer, Solid tumour, Fallopian tube cancer, Endometrial cancer, Obesity, Myelodysplastic syndrome
Regional status
US
Phase II
2016-05-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Prexigebersen?
Approved indications include: Acute myeloid leukaemia, Peritoneal cancer, Epithelial ovarian cancer, Solid tumour, Fallopian tube cancer, Endometrial cancer, Obesity, Myelodysplastic syndrome.
When does the Prexigebersen patent expire?
No public expiry year is available for Prexigebersen yet; this page updates once verified.
How do I get a quote for Prexigebersen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10